ClinicalTrials.gg
CompletedNCT02550652Updated Aug 27, 2024Results posted

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

A Phase 2 interventional study of Mycophenolate Mofetil/Mycophenolic Acid and Obinutuzumab in Lupus Nephritis, sponsored by Hoffmann-La Roche. Completed at 46 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.

Enrollment
5th of 11
126 · median 52
Started
2015
the only one that year
Phase 2
3 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 7th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Nephritis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Systemic Lupus Erythematosus (SLE), according to current American College of Rheumatology (ACR) criteria
  • Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal performed within 6 months prior to or during screening. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease
  • Proteinuria (urine protein to creatinine ratio) greater than (>) 1.0
  • For women who are not (greater than or equal to [>/=] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of , including at least one method with a failure rate of less than (\<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug
  • For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \<1% per year during the treatment period and for at least 12 months after the last dose of study drug and agreement to refrain from donating sperm during this same period

Exclusion criteria

Exclusion Criteria:

  • Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE
  • Presence of rapidly progressive glomerulonephritis
  • Severe renal impairment as defined by estimated (GFR) \<30 milliliters per minute (mL/min) or the need for dialysis or renal transplant
  • Greater than 50% of glomeruli with sclerosis on renal
  • Treatment with cyclophosphamide or calcineurin inhibitors within the 3 months prior to randomization
  • Unstable disease with thrombocytopenia or at high risk for developing bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or transfusions
  • History of severe allergic or anaphylactic reactions to monoclonal antibodies or known to any component of the obinutuzumab infusion
  • Significant or uncontrolled medical disease in any organ system not related to SLE or LN, which, in the investigator's opinion, would preclude participant participation
  • Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn's disease) that required oral or systemic use in the 52 weeks prior to screening
  • Previous treatment with an anti-cluster of differentiation (CD20)-targeted therapy within 12 months
  • Previous treatment with a biologic B-cell-targeted therapy (other than anti-CD20) within 6 months of randomization
  • Known intolerance to MMF or MPA
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Obinutuzumab

    Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.

    Drug: Mycophenolate Mofetil/Mycophenolic Acid · Drug: Obinutuzumab · Drug: Methylprednisolone · Drug: Prednisone

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.

    Drug: Mycophenolate Mofetil/Mycophenolic Acid · Other: Placebo · Drug: Methylprednisolone · Drug: Prednisone

Interventions

  • DrugMycophenolate Mofetil/Mycophenolic Acid

    Drug page: Mycophenolic Acid

    MMF/MPA will be administered as per schedule specified in the respective arm.

  • Obinutuzumab will be administered as per schedule specified in the respective arm.

    Also known as: Gazyva, GA101, RO5072759

  • OtherPlacebo

    Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.

  • Methylprednisolone IV will be administered as per schedule specified in the respective arm.

  • Prednisone will be administered as per schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52

    Percentage of participants with normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN range of central laboratory values.

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52

    OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of \<1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then urine protein:creatinine ratio of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF.

    Time frame: From baseline to Week 52

  2. Time to OR Over 52 Weeks

    OR includes both CRR and partial renal response(PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in upcr, with one of these conditions met: 1. If baseline upcr is ≤3.0, then upcr of \<1.0. 2. If baseline pcr is \> 3.0, then upcr of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF. Percentage of participants with response at various time points were measured using Kaplan Meier method.

    Time frame: From baseline to Week 52

  3. Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52

    PRR defined as serum creatinine ≤15% above baseline value, no urinary red cell casts and either RBCs/HPF ≤ 50% above baseline or \< 10 RBCs/HPF, 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then a urine protein:creatinine ratio of \< 1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then a urine protein:creatinine ratio of \< 3.0.

    Time frame: Week 52

  4. Percentage of Participants Who Achieve Protocol Defined CRR at Week 24

    CRR defined as normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.

    Time frame: Week 24

  5. Time to CRR Over 52 Weeks

    CRR included normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the ULN range of central laboratory values if baseline serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values. Percentage of participants with response at various time points were measured using Kaplan Meier method.

    Time frame: From Baseline to Week 52

  6. Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52

    Anti-dsDNA antibodies are a group of anti-nuclear autoantibodies targeting double stranded DNA.

    Time frame: Baseline and Week 52

  7. Change From Baseline in Complement Component 3 (C3) Levels at Week 52

    Complement C3 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.

    Time frame: Baseline and Week 52

  8. Change From Baseline in C4 Levels at Week 52

    Complement C4 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.

    Time frame: Baseline, Week 52

  9. Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52

    mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio \<0.5.

    Time frame: Week 52

  10. Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52

    mCRR2 is defined by normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts), and urinary protein to creatinine ratio \<0.5. Normalization of serum creatinine as evidenced by the following: Serum creatinine ≤15% above baseline if baseline (Day 1) serum creatinine is above the normal range of the central laboratory values or ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.

    Time frame: Week 52

  11. Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52

    mCRR3 is defined by normalization of serum creatine as evidenced by serum creatinine ≤ the ULN range of central laboratory values and urinary protein to creatinine ratio \< 0.5.

    Time frame: Week 52

  12. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs), Infections and Serious infections. The AEs reported do not include events after the receipt of rescue medications.

    Time frame: From baseline to approximately 7 years and 8 months

  13. Percentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia

    Infusion related reaction is defined as any event reported within 24 hours of infusion and thought to be causally related to the investigational agent by the investigator. Grade 3 or higher infections include all events of Grade 3 to 5 under the SOC of infections and infestations. Drug-related neutropenia is defined as events in the Roche AE Grouped Term (AEGT) "Neutropenia and associated complications" and thought to be causally related to the investigational agent by the investigator. Drug-related thrombocytopenia is defined as events in the Standard MedDRA Query (SMQ) "Haematopoietic Thrombocytopenia narrow" and thought to be causally related to the investigational agent by the investigator.

    Time frame: From baseline to approximately 7 years and 8 months

  14. Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab

    Antibodies are a blood protein produced in response to and counteracting a specific antigen.

    Time frame: From baseline to approximately 7 years and 8 months

  15. Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels

    CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.

    Time frame: Baseline, Week 2, Week 4, Week 12, Week 24, Week 52, Week 104, B Cell Follow-Up (Bcfu) at months 6, 12, 18, 24, 30, 36, 42 and 48

  16. Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab

    Time frame: Week 0, Week 24, Week 52

  17. Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab

    Time frame: Baseline to Week 52

  18. Systemic Clearance of Obinutuzumab

    Time frame: Day 0, Week 24, Week 52

  19. Volume of Distribution Under Steady State (Vss) of Obinutuzumab

    Time frame: Day 0, Week 24, Week 52

  20. Terminal Plasma Half-Life (t1/2) of Obinutuzumab

    Time frame: Day 0, Week 24, Week 52

  21. Change From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score

    Each VAS had a range from 0-100 with higher scores indicating greater symptom impact on global health status.

    Time frame: Baseline (Day 1), Weeks 4, 12, 24, 36, 52

07

Results

Posted Feb 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Started6362
Completed5544
Not completed818
Withdrew: Death14
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject47
Withdrew: Post trial access10
Withdrew: Lost to follow-up13
Withdrew: Physician decision02
Withdrew: Receipt of additional therapies that reduce peripheral b cell counts02

Outcome measures

PrimaryPercentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52

Percentage of participants with normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN range of central laboratory values.

Time frame:
From baseline to Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 522214
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.1145 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 12.3 · 95% CI -3.4 to 28.1
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.1145 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 12.3 · 80% CI 2.1 to 22.6Difference in Percentage of Participants
SecondaryPercentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52

OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of \<1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then urine protein:creatinine ratio of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF.

Time frame:
From baseline to Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 523522
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0246 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 20.1 · 95% CI 3.0 to 37.2
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0246 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 20.1 · 80% CI 8.9 to 31.3
SecondaryTime to OR Over 52 Weeks

OR includes both CRR and partial renal response(PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in upcr, with one of these conditions met: 1. If baseline upcr is ≤3.0, then upcr of \<1.0. 2. If baseline pcr is \> 3.0, then upcr of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF. Percentage of participants with response at various time points were measured using Kaplan Meier method.

Time frame:
From baseline to Week 52
Reported as:
Count of participants · Participants
Time to OR Over 52 Weeks
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Week 125559
Week 243337
Week 362129
Week 521421
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Log Rank · p = 0.0744
SecondaryPercentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52

PRR defined as serum creatinine ≤15% above baseline value, no urinary red cell casts and either RBCs/HPF ≤ 50% above baseline or \< 10 RBCs/HPF, 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then a urine protein:creatinine ratio of \< 1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then a urine protein:creatinine ratio of \< 3.0.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 523521
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0150 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 21.7 · 95% CI 4.7 to 38.7
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0150 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 21.7 · 80% CI 10.6 to 32.8
SecondaryPercentage of Participants Who Achieve Protocol Defined CRR at Week 24

CRR defined as normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined CRR at Week 24
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined CRR at Week 241617
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.8461 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: -2.0 · 95% CI -17.5 to 13.4
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.8461 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: -2.0 · 80% CI -12.1 to 8.1
SecondaryTime to CRR Over 52 Weeks

CRR included normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the ULN range of central laboratory values if baseline serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values. Percentage of participants with response at various time points were measured using Kaplan Meier method.

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Time to CRR Over 52 Weeks
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Week 126160
Week 244748
Week 363838
Week 522733
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Log Rank · p = 0.3530
SecondaryChange From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52

Anti-dsDNA antibodies are a group of anti-nuclear autoantibodies targeting double stranded DNA.

Time frame:
Baseline and Week 52
Reported as:
Mean · log IU/mL
Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52
log IU/mLOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52-0.810 ± 1.054-0.076 ± 1.103
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = <0.0001 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in adjusted mean: -0.81 · 95% CI -1.13 to -0.491
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = <0.0001 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in adjusted mean: -0.81 · 80% CI -1.019 to -0.602
SecondaryChange From Baseline in Complement Component 3 (C3) Levels at Week 52

Complement C3 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.

Time frame:
Baseline and Week 52
Reported as:
Mean · g/L
Change From Baseline in Complement Component 3 (C3) Levels at Week 52
g/LOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Change From Baseline in Complement Component 3 (C3) Levels at Week 520.311 ± 0.3020.106 ± 0.273
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = 0.0004 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in adjusted mean: 0.178 · 95% CI 0.081 to 0.275
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = 0.0004 · Difference in adjusted mean: 0.178 · 80% CI 0.115 to 0.241
SecondaryChange From Baseline in C4 Levels at Week 52

Complement C4 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.

Time frame:
Baseline, Week 52
Reported as:
Mean · g/L
Change From Baseline in C4 Levels at Week 52
g/LOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Change From Baseline in C4 Levels at Week 520.101 ± 0.1170.004 ± 0.164
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = <0.0001 · Difference in adjusted mean: 0.088 · 95% CI 0.052 to 0.124Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites).
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · ANCOVA · p = <0.0001 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in adjusted mean: 0.088 · 80% CI 0.065 to 0.112
SecondaryPercentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52

mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio \<0.5.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 522516
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0900 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%) · Difference in percentage of participants: 13.9 · 95% CI -2.4 to 30.1
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.0900 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%) · Difference in percentage of participants: 13.9 · 80% CI 3.2 to 24.5
SecondaryPercentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52

mCRR2 is defined by normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts), and urinary protein to creatinine ratio \<0.5. Normalization of serum creatinine as evidenced by the following: Serum creatinine ≤15% above baseline if baseline (Day 1) serum creatinine is above the normal range of the central laboratory values or ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 522821
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.1838 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%) · Difference in percentage of participants: 10.6 · 95% CI -6.4 to 27.6
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.1838 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%) · Difference in percentage of participants: 10.6 · 80% CI -0.5 to 21.7
SecondaryPercentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52

mCRR3 is defined by normalization of serum creatine as evidenced by serum creatinine ≤ the ULN range of central laboratory values and urinary protein to creatinine ratio \< 0.5.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 522924
Statistical analysis
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.3726 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%.) · Difference in percentage of participants: 7.3 · 95% CI -10.0 to 24.6
  • OBINUTUZUMAB 1000MG and MMF vs PLACEBO and MMF · Cochran-Mantel-Haenszel · p = 0.3726 (Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites). Statistically significant at pre-specified alpha of 20%) · Difference in percentage of participants: 7.3 · 80% CI -4.0 to 18.6
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs), Infections and Serious infections. The AEs reported do not include events after the receipt of rescue medications.

Time frame:
From baseline to approximately 7 years and 8 months
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events (AEs)
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Adverse Events5854
Grade 3 AEs1915
Grade 4 AEs67
Grade 5 AEs12
Serious Adverse Events1617
Infections4838
Serious infections510
SecondaryPercentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia

Infusion related reaction is defined as any event reported within 24 hours of infusion and thought to be causally related to the investigational agent by the investigator. Grade 3 or higher infections include all events of Grade 3 to 5 under the SOC of infections and infestations. Drug-related neutropenia is defined as events in the Roche AE Grouped Term (AEGT) "Neutropenia and associated complications" and thought to be causally related to the investigational agent by the investigator. Drug-related thrombocytopenia is defined as events in the Standard MedDRA Query (SMQ) "Haematopoietic Thrombocytopenia narrow" and thought to be causally related to the investigational agent by the investigator.

Time frame:
From baseline to approximately 7 years and 8 months
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia
ParticipantsOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Infusion Related Reactions106
Grade 3 or Higher Infections411
Drug-related Neutropenia32
Drug-related Thrombocytopenia00
SecondaryPercentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab

Antibodies are a blood protein produced in response to and counteracting a specific antigen.

Time frame:
From baseline to approximately 7 years and 8 months
Reported as:
Count of participants · Participants
Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab
ParticipantsOBINUTUZUMAB 1000MG and MMF
Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab7
SecondaryPercent Change From Baseline in Circulating CD19-Positive B-Cell Levels

CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.

Time frame:
Baseline, Week 2, Week 4, Week 12, Week 24, Week 52, Week 104, B Cell Follow-Up (Bcfu) at months 6, 12, 18, 24, 30, 36, 42 and 48
Reported as:
Mean · Percent change of cells/uL
Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels
Percent change of cells/uLOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Week 2-97.469 ± 12.89939.293 ± 145.247
Week 4-98.777 ± 5.235-5.186 ± 78.469
Week 12-97.045 ± 15.5060.661 ± 134.421
Week 24-96.628 ± 10.207-11.446 ± 86.793
Week 52-98.620 ± 5.67737.695 ± 220.857
Week 10477.123 ± 380.111-76.055 ± 31.519
Bcfu Month 6105.043 ± 402.281-73.889 ± 19.755
Bcfu Month 1277.123 ± 380.111-76.055 ± 31.519
Bcfu Month 18-83.159 ± 16.701-11.418 ± NA
Bcfu Month 24-93.603 ± 8.836—
Bcfu Month 30-59.950 ± 50.807—
Bcfu Month 36-99.163 ± 0.973—
Bcfu Month 42-99.084 ± NA—
Bcfu Month 48-99.851 ± NA—
SecondaryMaximum Observed Plasma Concentration (Cmax) of Obinutuzumab
Time frame:
Week 0, Week 24, Week 52
Reported as:
Mean · ug/mL
Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab
ug/mLOBINUTUZUMAB 1000MG and MMF
Week 0-24559 ± 112
Week 24-52605 ± 115
Week 0-52605 ± 115
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab
Time frame:
Baseline to Week 52
Reported as:
Mean · ug/mL*day
Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab
ug/mL*dayOBINUTUZUMAB 1000MG and MMF
Week 0-2410595 ± 4016
Week 24-5215811 ± 5543
Week 0-5226406 ± 9027
SecondarySystemic Clearance of Obinutuzumab
Time frame:
Day 0, Week 24, Week 52
Reported as:
Mean · L/day
Systemic Clearance of Obinutuzumab
L/dayOBINUTUZUMAB 1000MG and MMF
Day 00.255 ± 0.136
Week 240.147 ± 0.0564
Week 520.137 ± 0.0535
SecondaryVolume of Distribution Under Steady State (Vss) of Obinutuzumab
Time frame:
Day 0, Week 24, Week 52
Reported as:
Mean · Litre (L)
Volume of Distribution Under Steady State (Vss) of Obinutuzumab
Litre (L)OBINUTUZUMAB 1000MG and MMF
Day 03.67 ± 0.591
Week 243.67 ± 0.591
Week 523.67 ± 0.591
SecondaryTerminal Plasma Half-Life (t1/2) of Obinutuzumab
Time frame:
Day 0, Week 24, Week 52
Reported as:
Mean · day
Terminal Plasma Half-Life (t1/2) of Obinutuzumab
dayOBINUTUZUMAB 1000MG and MMF
Day 013.1 ± 3.7
Week 2420.5 ± 5.6
Week 5222.1 ± 6.7
SecondaryChange From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score

Each VAS had a range from 0-100 with higher scores indicating greater symptom impact on global health status.

Time frame:
Baseline (Day 1), Weeks 4, 12, 24, 36, 52
Reported as:
Mean · score on scale
Change From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score
score on scaleOBINUTUZUMAB 1000MG and MMFPLACEBO and MMF
Baseline41.3 ± 25.5939.4 ± 24.76
Week 4-14.4 ± 18.28-8.7 ± 22.69
Week 12-19.9 ± 25.07-11.6 ± 25.22
Week 24-25.0 ± 25.17-20.8 ± 24.74
Week 36-24.8 ± 25.71-19.6 ± 25.04
Week 52-25.4 ± 26.49-23.3 ± 25.76

Adverse events

Collected over From baseline to approximately 7 years and 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OBINUTUZUMAB 1000MG + MMF1/64 (1.6%)17/64 (26.6%)51/64 (79.7%)
PLACEBO + MMF4/61 (6.6%)18/61 (29.5%)39/61 (63.9%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventOBINUTUZUMAB 1000MG + MMFPLACEBO + MMF
HERPES ZOSTERInfections and infestations1/643/61
SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders2/642/61
RENAL FAILURERenal and urinary disorders0/642/61
PYREXIAGeneral disorders2/641/61
ABDOMINAL PAINGastrointestinal disorders2/640/61
NEUTROPENIABlood and lymphatic system disorders1/641/61
THROMBOCYTOPENIABlood and lymphatic system disorders0/641/61
CARDIAC FAILURECardiac disorders0/641/61
INTESTINAL PERFORATIONGastrointestinal disorders0/641/61
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders0/641/61
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOBINUTUZUMAB 1000MG + MMFPLACEBO + MMF
URINARY TRACT INFECTIONInfections and infestations14/6412/61
BRONCHITISInfections and infestations13/645/61
INFUSION RELATED REACTIONInjury, poisoning and procedural complications7/646/61
GASTROENTERITISInfections and infestations3/646/61
HERPES ZOSTERInfections and infestations5/646/61
NASOPHARYNGITISInfections and infestations5/646/61
NAUSEAGastrointestinal disorders6/643/61
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations6/645/61
HYPERTENSIONVascular disorders6/642/61
DIARRHOEAGastrointestinal disorders3/645/61

Baseline characteristics

Age, Continuous
Age, Continuous(Years)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Mean33.1 ± 9.831.9 ± 10.132.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Female5551106
Male81119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Hispanic Or Latino424991
Not Hispanic Or Latino201232
Not Stated101
Unknown011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
American Indian or Alaska Native111728
Asian325
Black or African American6511
Multiple101
Native Hawaiian or other Pacific Islande101
Unknown131225
White282654
Circulating CD19-Positive B-Cell Levels
Circulating CD19-Positive B-Cell Levels(cells/uL)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Mean328 ± 331353 ± 454341 ± 395
Region of Enrollment
Region of Enrollment(Participants)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Asia224
European Union16521
Latin America374683
United States7815
Lupus Nephritis (LN) Biopsy Class
Lupus Nephritis (LN) Biopsy Class(Participants)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
III141731
IV494594
Urine Protein Creatinine Ratio (UPCR)
Urine Protein Creatinine Ratio (UPCR)(mg/mg)OBINUTUZUMAB 1000MG and MMFPLACEBO and MMFTotal
Mean3.32 ± 2.662.93 ± 2.463.12 ± 2.56

1 further baseline measures are reported on the registry.

08

Study locations

46 sites
  • Univ of California, San Diego
    La Jolla, California 92093, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Emory Uni ; Division of Rheumatology
    Atlanta, Georgia 30303, United States
  • Suny Downstate Medical Center; Rheumatology
    Brooklyn, New York 11203, United States
  • North Shore - Long Island Jewish Hospital Health System; Rheumatology & Allergy- Clinical Immunology
    Great Neck, New York 11021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Ohio State University; Division of Nephrology
    Columbus, Ohio 43210, United States
  • Cemic; Haematology
    Buenos Aires, C1431FWO, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
    San Juan, J5400DIL, Argentina
  • Organizacion Medica de Investigacion
    San Nicolás, C1015ABO, Argentina
  • Ser Servicos Especializados Em Reumatologia
    Salvador, BA 40150-150, Brazil
  • Hospital das Clinicas - UFMG
    Belo Horizonte, MG 31270-901, Brazil
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, MG 36010-570, Brazil
  • Instituto Scribner.
    Curitiba, PR 80440-020, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, RS 90480-000, Brazil
  • Universidade Federal de Sao Paulo - UNIFES
    Sao Paulo, SP 04026-000, Brazil
  • Clinica De La Costa
    Barranquilla, 080020, Colombia
  • Hospital Universitario San Ignacio
    Bogota, 000472, Colombia
  • Riesgo De Fractura; Rheumatology
    Bogota, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, 050034, Colombia
  • Hospital Clinica Catolica
    Goicoechea, 10801, Costa Rica
  • HOPITAL HENRI MONDOR; SERVICE DE Nephrologie
    Creteil, 94010, France
  • Hopital Claude Huriez; Internal Medicine
    Lille, 59037, France
  • Hopital europeen Marseille; Service de medecine interne
    Marseille, 13003, France
  • Groupe Hospitalier Pitie-Salpetriere; Service de Medecine Interne Ii
    Paris, 75651, France
  • Hopital Bichat Claude Bernard; Nephrologie
    Paris, 75877, France
  • Hopital Rangueil; Service de Nephrologie & D'Immunologie Clinique
    Toulouse, 31059, France
  • Rambam Medical Center; Rheumatology
    Haifa, 3109601, Israel
  • Beilinson Medical Center; Rheumatology
    Petach Tikva, 4941492, Israel
  • Sheba Medical Center; Tel Hashomer
    Ramat Gan, 5262100, Israel
  • Ospedale San Giovanni Bosco; entro di Ricerche di Immunopatologia e Documentazione su Malattie Rare
    Torino, Piemonte 10154, Italy
  • Azienda Ospedaliera di Padova; Dipartimento di Medicina - UOC di Reumatologia
    Padova, Veneto 35128, Italy
  • Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel
    Mexicali, BAJA California 21100, Mexico
  • Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia
    Guadalajara, Jalisco 44620, Mexico
  • Centro de Estudios de Investigacion Basica Y Clinica S.C.; Reumatologia
    Guadalajara, Jalisco 44690, Mexico
  • Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
    Mexico City, Mexico CITY (federal District) Tlalpan 14000, Mexico
  • Hospital General De Mexico; Rheumatology
    Mexico, D.F., Mexico CITY (federal District) 6726, Mexico
  • Centro de Investigación Clínica de Morelia S.C.
    Morelia, Michoacan 58070, Mexico
  • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)
    Culiacán Rosales, Sinaloa 80000, Mexico
  • Trial Labs
    Panama, 0801, Panama
  • Instituto de Ginecología y Reproducción
    Lima, Peru
  • Centro de Investigación Delgado; Clinica Delgado
    Miraflores, 15074, Peru
  • Centro de Investigaciones Medicas/Hospital Maria Auxiliadora
    San Juan de Miraflores, 15801, Peru
  • Hospital Nacional Cayetano Heredia; Rheumatology
    San Martin de Porres, 15102, Peru
  • Hospital Clinic i Provincial; Servicio de Nefrologia
    Barcelona, 08036, Spain
  • Hospital Regional Universitario Carlos Haya; Servicio de Reumatologia
    Malaga, 29009, Spain
09

References and documents

Publications

  • Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P, Looney CM, Hassan I, Malvar A. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920. Epub 2021 Oct 6. PubMed 34615636 ↗
  • Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. No abstract available. PubMed 33693991 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jan 2019, 38 months.

Results were first posted in Feb 2020, 1 year 1 month after primary completion.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2015
First posted
Sep 15, 2015
StartActual
Nov 13, 2015
Primary completionActual
Jan 15, 2019
CompletionActual
Aug 2, 2023
Results first posted
Feb 26, 2020
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02550652
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Nov 13, 2015
Primary completion
Jan 15, 2019
Completion
Aug 2, 2023
Results posted
Feb 26, 2020
Last update
Aug 27, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion